Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

AMLM22/D1

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission

Open for recruitment

Trial summary

AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Trial details

Short title

AMLM22/D1

Diagnosis

Leukaemia

Type of treatment

Haematology

Phase

II

Locations

Wesley Southport South Brisbane Chermside

Investigators

Dr Joseph Clarey Dr Raymond Banh Dr Robert Hensen A/Prof James Morton AM

Principal Investigators

Who can participate

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.

Find out more View other clinical trials